[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
作者信息
Kalenka Armin
出版信息
Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698-9; author reply 1699-70. doi: 10.1055/s-2004-829020.
PMID:15273924
Abstract
摘要
相似文献
1
[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698-9; author reply 1699-70. doi: 10.1055/s-2004-829020.
2
[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698; author reply 1699-70. doi: 10.1055/s-2004-829019.
3
Appraisal of treatment for severe sepsis in intensive care units.
Ann R Coll Surg Engl. 2005 Jul;87(4):283-4.
4
Recombinant factor VIIa should be used in massive obstetric haemorrhage.
Int J Obstet Anesth. 2007 Oct;16(4):357-9. doi: 10.1016/j.ijoa.2007.06.002. Epub 2007 Aug 15.
5
Cost-effectiveness of drotrecogin alfa (activated).
Crit Care Med. 2003 Sep;31(9):2414-5; author reply 2415. doi: 10.1097/01.CCM.0000087000.98485.5D.
6
[Expensive modern therapy options in intensive care medicine in Germany-- are they being used? Results of a questionnaire].
Dtsch Med Wochenschr. 2005 Jan 21;130(3):87-91. doi: 10.1055/s-2005-837379.
7
Recombinant factor VIIa should be used in massive obstetric haemorrhage.
Int J Obstet Anesth. 2007 Oct;16(4):354-7. doi: 10.1016/j.ijoa.2007.06.001. Epub 2007 Aug 14.
8
Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
Emerg Med Australas. 2004 Aug;16(4):324-35. doi: 10.1111/j.1742-6723.2004.00630.x.
9
Traumatic haemorrhage: a role for recombinant factor VIIa?
Anaesthesia. 2009 Oct;64(10):1141-2. doi: 10.1111/j.1365-2044.2009.06086.x.
10
Evidence and desperation in off-label prescribing: recombinant factor VIIa.
BMJ. 2012 Jan 16;344:d7926. doi: 10.1136/bmj.d7926.
Zotero 插件